Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP)

• Hitoshi Hashimoto

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Norihito Shintani

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Kazuhiro Tanaka

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Wakaba Mori

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Megumi Hirose

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Toshio Matsuda

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Masaki Sakaue

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Jun-ichi Miyazaki

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Hitoshi Niwa

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Fumi Tashiro

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Kyohei Yamamoto

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Kazumi Koga

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Shuhei Tomimoto

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Akiyoshi Kunugi

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Sayoko Suetake

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

• Akemichi Baba

  Laboratories of Molecular Neuropharmacology and Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Laboratory of Molecular Pharmacology, Graduate School of Medicine, and Division of Stem Cell Regulation Research, Osaka University Medical School, Osaka University, Suita, Osaka 565-0871, Japan

抄録

Pituitary adenylate cyclase-activating polypeptide (PACAP) has been conserved remarkably during evolution and is widely expressed in the mammalian brain. In Drosophila , mutation of the PACAP homologue results in behavioral defects, including impaired olfaction-associated learning and changes in ethanol sensitivity. Here, we report the generation of mice lacking the PACAP gene (PACAP −/− ). PACAP −/− mice were born in the expected Mendelian ratios but had a high early-mortality rate. The surviving adult PACAP −/− mice displayed remarkable behavioral changes; they exhibited hyperactive and explosive jumping behaviors in an open field, increased exploratory behavior, and less anxiety in the elevated plus maze, emergence, and novel-object tests. Analysis of PACAP −/− mice brains revealed that the serotonin metabolite 5-hydroxyindoleacetic acid was slightly decreased in the cortex and striatum compared with wild-type mice. The present study provides evidence that PACAP plays a previously uncharacterized role in the regulation of psychomotor behaviors.

収録刊行物

• Proceedings of the National Academy of Sciences

  Proceedings of the National Academy of Sciences 98 (23), 13355-13360, 2001-10-30

  Proceedings of the National Academy of Sciences

キーワード

• Multidisciplinary

詳細情報

• CRID: 1360855569826846720
• NII論文ID: 80012878063
• DOI: 10.1073/pnas.231094498
• ISSN: 10916490
• ISSN: 00278424
• Web Site: https://pnas.org/doi/pdf/10.1073/pnas.231094498
• データソース種別:
  • Crossref
  • CiNii Articles